Search

Introduction: Physical match actions are simulated through modified games. Pitch size and set configuration seems to influence the physical responses during small-sided games. Objective: The aim of the present study is to analyze the effects of pitch size and set configuration during small-sided games. Methodology: Fourteen young male field soccer players performed three small-sided games, involving 7 vs. 7 + 2 goalkeepers: 3 x 8 min with 5 min of rest between sets on a 68 x 40 m pitch (194 m2); same pitch area but 6 x 4 min with 2 min of rest (194 m2); and 6 x 4 min with 2 min of rest on a 40 x 34 m pitch (97 m2). Vertical jump, kick velocity and sprint were assessed to examine the residual fatigue before and after each small-sided game. Results: Larger pitch sizes showed significantly higher physical demands. Shorter bouts demanded greater distances at high intensity than longer bouts. A significant SSG x time interaction was observed for 10-m sprint time (P = 0.04), where a greater impairment was observed after completing 6 x 4 min (194 m2). Discussion: Higher external loads have been observed during games on larger pitches. A 4 min bout was provided as the optimal physical training stimulus. Conclusions: Larger pitch sizes and shorter bout durations are higher-demand games than smaller pitch sizes and longer bouts. Sprint performance is impaired after completing every small-sided game, especially acceleration capacity after completing modified games involving larger pitch areas and shorter bout durations.

Despite the efficacy of selective serotonin reuptake inhibitors (SSRIs) in the treatment of major depression, a significant number of patients show partial or no remission of symptoms. Some evidence suggests that psychostimulant augmentation may be helpful in treating patients with residual symptoms of depression. The efficacy of modafinil in augmenting SSRIs in depressed patients with residual fatigue or excessive daytime sleepiness has yet to be systematically investigated. In a series of 25 patients with major depressive disorder, according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, who showed significant residual symptoms after an adequate SSRI trial (12 wk) and who were evaluated according to the Fatigue Severity Scale (FSS), subjects with scores ≥4 were given open-label modafinil augmentation for a minimum of an additional 6 wk. Treatment response was assessed prospectively with the FSS, the Epworth Sleepiness Scale (ESS), and the Hamilton Rating Scale for Depression (HAM-D) during the first visit and at the second and sixth weeks. Twenty-one of 25 patients in this series who were treated with modafinil and SSRIs completed the 6-wk augmentation trial. At end-point assessment, all patients showed significant improvement in fatigue and sleepiness in FSS and ESS scores, as well as in HAM-D scores ( P< .01). In the second week, 29.4% of patients had a HAM-D score < 7, which was defined as remission; this rate was 64.7% in the sixth week. The rate of patients whose HAM-D score dropped by more than 50%, defined as responders to treatment, was 41.1% and 76.4% in the second and sixth weeks, respectively. Results of this preliminary, open-label trial suggest that modafinil may be effective in augmenting ongoing SSRI treatment for a portion of patients with major depression who have residual fatigue and sleepiness. Larger, placebo-controlled trials appear warranted to investigate the clinical efficacy and tolerability of modafinil augmentation of SSRI treatment in these patients. [ABSTRACT FROM AUTHOR]